English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

To determine whether baseline characteristics had an impact on clinical outcomes in the  LixiLan‐O  trial (N = 1170), we compared the efficacy and safety of  iGlarLixi , a titratable fixed‐ratio combination of insulin glargine 100 U ( iGlar ) and lixisenatide (Lixi) with  iGlar  or Lixi alone in patients with uncontrolled type 2 diabetes mellitus ( T2DM ) on oral therapy. Subgroups according to baseline glycated haemoglobin ( HbA1c ; <8% or ≥8% [<64 or ≥64 mmol/mol]),  T2DM  disease duration (<7 or ≥7 years) and body mass index ( BMI ; <30 or ≥30 kg/m 2 ) were investigated. In all subpopulations,  iGlarLixi  was consistently statistically superior to  iGlar  and Lixi alone in reducing  HbA1c  from baseline to week 30; higher proportions of patients achieved  HbA1c  <7% (<53 mmol/mol) with  iGlarLixi  vs  iGlar  and Lixi alone. Compared with  iGlar ,  iGlarLixi  resulted in a substantial decrease in 2‐hour postprandial plasma glucose levels, and mitigation of weight gain, with no differences among subpopulations in incidence of symptomatic hypoglycaemia.  iGlarLixi  consistently improved glycaemic control compared with  iGlar  and Lixi alone, without weight gain or increase in hypoglycaemic risk compared with  iGlar  in the subpopulations tested, regardless of baseline  HbA1c , disease duration and  BMI .

diabetes, obesity and metabolism

Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the  LixiLan‐O  trial testing a titratable fixed‐ratio combination of insulin glargine/lixisenatide ( iGlarLixi ) vs insulin glargine and lixisenatide monocomponents